View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

GSK: 1 director

A director at GSK sold 6,000 shares at 1,702p and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close p...

Jerôme Bodin
  • Jerôme Bodin

ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024

Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...

Jerôme Bodin
  • Jerôme Bodin

ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024

Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)

This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...

Jerôme Bodin
  • Jerôme Bodin

JCDecaux : Solid advertising momentum, upgrade to our estimates. Outpe...

>Outperform rating confirmed - JCDecaux’s Q1 sales, reported yesterday evening, beat our expectations, with organic growth of 11% vs our forecast of 9.5% and the group’s guidance of 9%. The start of the year is thus solid and very robust, although the situation in China remains lacklustre. The group did not hold a conference call but its organic growth guidance is 12% for Q2, while we forecast 9.5% and the consensus around 9%. Note the fairly tough comps in Q2, with +...

Benoit Valleaux ... (+2)
  • Benoit Valleaux
  • Steven Gould

Santander : A robust start to 2024 and guidance confirmed

>Outperform rating maintained - Target price raised to € 5.5 (vs € 5.4) - Santander’s Q1 2024 results underpin our Outperform rating and lead us to increase our net profit estimates (+2% on average over the period 2024-2026e), due to a slightly more favourable stance on the top line trend. Our target price has thus been lifted to € 5.5 (vs € 5.4). The trend in the group’s operating performances remains broadly solid with the validation of the main financial targets se...

Benoit Valleaux ... (+2)
  • Benoit Valleaux
  • Steven Gould

Santander : Début d’année 2024 solide & guidances confirmées

>Opinion Surperformance maintenue – OC porté à 5.5 € (vs 5.4 €) - Les résultats T1 2024 de Santander viennent conforter notre opinion Surperformance et nous amènent à rehausser nos estimations de RN (+2% en moyenne sur la période 2024-26), en raison d’un biais un peu plus favorable notamment sur l’évolution de la topline. Notre OC est en conséquence porté à 5.5 € (vs 5.4 €). L’évolution des performances opérationnelles du groupe reste globalement solides avec une vali...

Jerôme Bodin
  • Jerôme Bodin

JCDecaux : Solide dynamique publicitaire, relèvement de nos attentes. ...

>Opinion Surperformance réitérée - JCDecaux a publié hier soir un CA T1 supérieur à notre attente avec une croissance organique de 11% alors que nous tablions sur 9,5% et le groupe avait guidé sur 9%. Le début d’année ressort donc solide et très dynamique mais toujours avec une situation en Chine « poussive ». Le groupe n’a pas tenu de conférence téléphonique mais il guide sur une croissance organique de 12% sur le T2 alors que nous tablions sur 9,5% et le consensus a...

 PRESS RELEASE

JCDecaux : Q1 2024 trading update

JCDecaux : Q1 2024 trading update          Q1 2024 trading update Q1 2024 adjusted revenue up +11.1 % to €801.6 million Q1 2024 adjusted organic revenue up +11.0% Q2 2024 adjusted organic revenue growth expected to be around +12.0% Paris, May 2nd, 2024 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announced today its revenue for the first quarter 2024. Commenting on the 2024 first quarter revenue, Jean-François Decaux, Chai...

Anthony Dick ... (+2)
  • Anthony Dick
  • Michael Foundoukidis

Volkswagen (pref) : A tough start to the year, unlikely to improve sen...

>Q1 even tougher than expected but with no consequence for the year - Although VW had expected a tough Q1, earnings were nonetheless 7% below estimates (EBIT) with an operating margin of 6.1% (consensus at 6.5%) and negative FCF of close to € 3bn (vs consensus at -€ 921m). The causes were known, but had an even more negative impact than anticipated, mainly with the supply difficulties at Audi (operating margin for Progressive unit at just 3.4% vs consensus 7.7%) and, ...

Anthony Dick ... (+2)
  • Anthony Dick
  • Michael Foundoukidis

Volkswagen (pref) : Un début d’année difficile, pas de nature à amélio...

>Un T1 encore plus difficile qu’anticipé mais sans conséquence sur l’année - Si VW avait bien prévenu d’un T1 difficile, les résultats sont néanmoins ressortis inférieurs de 7% aux attentes (EBIT) avec une MOP de 6.1% (consensus à 6.5%) et un FCF négatif de près de 3 Md€ (vs consensus à -921 M€). Les causes étaient connues mais ont eu un impact encore plus négatif qu’anticipé avec, essentiellement, les difficultés d’approvisionnement chez Audi (MOP Progressive à seule...

 PRESS RELEASE

Press Release: Beyfortus real-world evidence published in The Lancet s...

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...

 PRESS RELEASE

Communiqué de presse : Des données de vie réelle concernant Beyfortus ...

Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...

Sanofi: 1 director

A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch